Open AccessCore‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐ CBF it)
Author(s) -
Ustun Celalettin,
Morgan Elizabeth,
Moodie Erica E. M.,
Pullarkat Sheeja,
Yeung Cecilia,
BroesbyOlsen Sigurd,
Ohgami Robert,
Kim Young,
Sperr Wolfgang,
Vestergaard Hanne,
Chen Dong,
Kluin Philip M.,
Dolan Michelle,
Mrózek Krzysztof,
Czuchlewski David,
Horny HansPeter,
George Tracy I.,
Kristensen Thomas Kielsgaard,
Ku Nam K.,
Yi Cecilia Arana,
Møller Michael Boe,
Marcucci Guido,
Baughn Linda,
Schiefer AnaIris,
Hilberink J. R.,
Pullarkat Vinod,
Shanley Ryan,
Kohlschmidt Jessica,
Coulombe Janie,
Salhotra Amandeep,
Soma Lori,
Cho Christina,
Linden Michael A.,
Akin Cem,
Gotlib Jason,
Hoermann Gregor,
Hornick Jason,
Nakamura Ryo,
Deeg Joachim,
Bloomfield Clara D.,
Weisdorf Daniel,
Litzow Mark R.,
Valent Peter,
Huls Gerwin,
Perales MiguelAngel,
Borthakur Gautam
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1733
Subject(s) - medicine , core binding factor , myeloid leukemia , oncology , white blood cell , myeloid , hematopoietic cell , transplantation , risk factor , leukemia , hematopoietic stem cell transplantation , gastroenterology , haematopoiesis , stem cell , gene , chemistry , genetics , biology , transcription factor , biochemistry
Background Although the prognosis of core‐binding factor ( CBF ) acute myeloid leukemia ( AML ) is better than other subtypes of AML , 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (allo HCT ). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results Complete remission ( CR ) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received allo HCT . The median disease‐free ( DFS ) and overall ( OS ) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts ( WBC ), and pseudodiploidy compared with hyper‐ or hypodiploidy were included in a scoring system (named I‐ CBF it). DFS rate at 2 years was 76% for patients with a low‐risk I‐ CBF it score compared with 36% for those with a high‐risk I‐ CBF it score ( P < 0.0001). Low‐ vs high‐risk OS at 2 years was 89% vs 51% ( P < 0.0001). Conclusions I‐ CBF it composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom allo HCT is not need in CR 1 (ie, patients with a low‐risk I‐ CBF it score).